Predictive Role of Circulating Immune Cell Subtypes Early After Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia
Overview
Authors
Affiliations
Background And Objectives: Cells of innate immunity normally recover in the first weeks to months after allogenenic hematopoietic stem cell transplantation (allo-HSCT). Their relevance in terms of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect is largely unknown. The predictive role of early recovery in the immune cells on acute GVHD and GVL effect after allo-HSCT was investigated in patients with acute leukemia who achieved the first complete remission.
Methods: Peripheral blood samples were taken at the median of 14 days (range, 12∼29 days) after allo-HSCT. A cohort including 119 samples and characteristics of patients were analyzed. Immune cell populations were identified by flow cytometry.
Results: The median age was 49.0 years (range, 21∼69) at transplantation. Univariate analysis showed that age less than 40 years old, lower frequencies of CD8 T cells, invariant natural killer T (iNKT) cells, monocytic myeloid derived suppressor cells (M-MDSCs) and higher frequency of immature MDSCs were associated with occurrence of grade III-IV acute GVHD. Multivariate analyses showed that iNKT cells (hazard ratio (HR), 0.453, 95% CI, 0.091∼0.844, p=0.024) and M-MDSCs (HR, 0.271, 95% CI, 0.078∼0.937, p=0.039) were independent factors. Combination of higher frequencies of both cell subsets was associated with lower incidence of grade III-IV acute GVHD, whereas patients with lower frequency of iNKT cells and higher frequency of M-MDSCs showed significant higher probability of relapse.
Conclusions: iNKT cells and M-MDSCs could be relevant cell biomarkers for predicting acute GVHD and/or relapse in acute leukemia patients treated with allo-HSCT.
Guan Q, Gilpin S, Doerksen J, Bath L, Lam T, Li Y Cells. 2024; 13(18.
PMID: 39329729 PMC: 11429538. DOI: 10.3390/cells13181545.
Notarantonio A, Bertrand A, Piucco R, Fievet G, Sartelet H, Boulange L Exp Hematol Oncol. 2024; 13(1):50.
PMID: 38734654 PMC: 11088072. DOI: 10.1186/s40164-024-00516-4.
Peterlin P, Bene M, Jullien M, Guillaume T, Le Bourgeois A, Garnier A EJHaem. 2023; 4(4):1089-1095.
PMID: 38024608 PMC: 10660606. DOI: 10.1002/jha2.795.
Wang W, Li H, Guo Y, Zhang L, Jiang W, Zheng N Clin Exp Immunol. 2023; 215(2):148-159.
PMID: 37971356 PMC: 10847816. DOI: 10.1093/cei/uxad123.
Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies.
Bhardwaj V, Ansell S Front Cell Dev Biol. 2023; 11:1129343.
PMID: 37091970 PMC: 10113446. DOI: 10.3389/fcell.2023.1129343.